Enlivex Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Oren Hershkovitz

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	5yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Recent updates

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Sep 13

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Apr 04

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Dec 13

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Jul 25

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Apr 05

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Nov 16

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 30

Enlivex to gets US patent covering use of cell therapy Allocetra

Sep 06

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Aug 29

Envilex Therapeutics reports Q2 results

Aug 22

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Jul 08

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Jul 06

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Mar 23

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Nov 25

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Aug 12

Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy

Jun 15

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Jan 11

Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

Nov 19

Analyse CEO-vergoeding

Hoe is Oren Hershkovitz's beloning veranderd ten opzichte van Enlivex Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$22m
Mar 31 2024	n/a	n/a	-US$26m
Dec 31 2023	n/a	n/a	-US$29m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	n/a	n/a	-US$31m
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$26m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	n/a	n/a	-US$12m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$296k	US$38k	-US$10m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Oren redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Oren te vergelijken met de prestaties van het bedrijf.

CEO

Oren Hershkovitz (47 yo)

5yrs

Tenure

US$295,600

Compensatie

Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shai Novik	Executive Chairman	10.8yrs	US$536.00k	3.62% $ 994.6k
Oren Hershkovitz	Chief Executive Officer	5yrs	US$295.60k	0.12% $ 32.8k
Shachar Shlosberger	Chief Financial Officer	8.8yrs	US$132.00k	0.0088% $ 2.4k
Veronique Amor-Baroukh	Senior Director of Operations	2.8yrs	geen gegevens	geen gegevens
Sigal Arad	Director of HR	2.8yrs	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ENLV is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shai Novik	Executive Chairman	10.8yrs	US$536.00k	3.62% $ 994.6k
Andrew Singer	Independent Director	1.6yrs	geen gegevens	geen gegevens
Abraham Havron	Independent Director	10.8yrs	geen gegevens	0.85% $ 232.9k
Mitchell Levy	Clinical Advisor	no data	geen gegevens	geen gegevens
Roger Pomerantz	Independent Vice Chairman of the Board	2.5yrs	geen gegevens	0% $ 0
Brian Schwartz	Director	3.9yrs	geen gegevens	0.013% $ 3.5k
Clifford Deutschman	Clinical Advisor	no data	geen gegevens	geen gegevens
David Hunter	Clinical Advisor	less than a year	geen gegevens	geen gegevens
Bruno Francois	Clinical Advisor	less than a year	geen gegevens	geen gegevens
Gili Hart	Independent Director	10.8yrs	geen gegevens	0.024% $ 6.5k
Ali Mobasheri	Clinical Advisor	less than a year	geen gegevens	geen gegevens
Tobias Winkler	Clinical Advisor	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ENLV wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.

Enlivex Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Recent updates

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

High number of new and inexperienced directors

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased by 20% to US$12.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Intends to Reduce its Workforce by Approximately 50%

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

New major risk - Financial position

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Enlivex Receives Allocetra Ind Clearance from the U.S. Food and Drug Administration for Treatment of Patients with Advanced Solid Malignancies

Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$15.00

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

Enlivex to gets US patent covering use of cell therapy Allocetra

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Enlivex Therapeutics Ltd. Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Envilex Therapeutics reports Q2 results

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Sheba Medical Center and Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Enlivex Therapeutics Ltd. Receives Israeli Ministry of Health Authorization for the Initiation of Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Price target increased to US$33.00

Insufficient new directors

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand Its Phase IIb Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients into Greece

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

Independent Director notifies of intention to sell stock

Enlivex Therapeutics Ltd.: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy

Enlivex issued new Canadian patent for Allocetra immunotherapy

Enlivex Awards Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn